UBS analyst Trung Huynh maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $31.00. The ...

On Friday, Pfizer Inc (PFE) stock saw a decline, ending the day at $26.72 which represents a decrease of $-0.74 or -2.69% from the prior close of $27.46. The stock opened at $27.11 and touched a low ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00 ... corporate insider sentiment is neutral on the stock. Last month, ...

But making Pfizer Inc an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Pfizer is expected to post ...

For PFE stock options expiring on Dec. 20, 2024, this exercise yields a price of $2.55. In other words, from Friday’s close of $28.09, PFE may move up to $30.64 or fall down to $25.54.